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Abstract 
The concept of composite tissue allotransplantation (CTA) for restoration of congenital or acquired deformities is not new 
and the recent success of clinical composite tissue allotransplantation (CTA) attests to the fact that composite tissue allografts have 
tremendous potential in these life-enhancing reconstructions. A hand transplant, unlike a solid organ transplant, involves multiple 
tissues (skin, muscle, tendon, bone, cartilage, fat, nerves and blood vessels) and can be considered the “gold standard” in CTA. In 
this regard, no other organ or tissue transplant matches the hand transplant in its immunogenicity as well as complexity. 
Development of assays that allow us to monitor the current state of an immune response (rejection/tolerance) is of great interest and  
requires an in-depth understanding of the complex and rare phenomenon of tolerance. 
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Review 
Each year, an estimated 7-million people in the 
USA need composite tissue reconstruction because of 
surgical excision of tumors, accidents and congenital 
malformations. The recent success of clinical composite 
tissue allotransplantation (CTA) attests to the fact that 
composite tissue allografts have tremendous potential in 
these life-enhancing reconstructions. 
The concept of CTA for restoration of congenital 
or acquired deformities is not new. In fact, one of the first 
accounts of transplantation dates back to c. 348 A.D. in 
which the sainted twins Cosmas and Damien replaced the 
gangrenous, cancerous leg of a sleeping man with that of 
a recently deceased Ethiopian Moor.  Then in the 16th 
century in Bologna, Italy, Gaspare Tagliacozzi, whom 
many regard as the “father of plastic surgery”, reportedly 
used a flap of tissue transplanted from a slave to 
reconstruct the severed nose of a man. In November 
1997, in Louisville, Kentucky, USA was held the 1st 
International Symposium on CTA. At this meeting, 
reconstructive and transplant surgeons, immunologists, 
scientists and ethicists from around the world came 
together to discuss “the scientific, clinical, and ethical 
barriers standing in the way of performing the first 
successful human hand transplant” [1] . Based on these 
findings, on September, 1998, was performed the first 
successful human hand transplant using 
tacrolimus/MMF/prednisone-based combination therapy, 
in Lyon, France by a team directed by J.-M. 
DUBERNARD. A 48-year old man with a right-hand 
amputation received a forearm transplant harvested from 
a 41-year old man in cadaveric (brain dead) status. The 
procedure was not considered by all as an advance in 
hand surgery [2], but it will be remembered as a major 
step in the history of Man, as were the first kidney 
(Murray, 1954) and heart transplantations (Barnard, 1967) 
[3].  
The procedure is for individuals who have 
experienced the difficult loss of a hand or forearm due to: 
(1) trauma; (2) life saving interventions that caused 
permanent injury to the hand or forearm.  At this time, 
hand transplant procedure is not being considered for 
congenital anomalies, loss of a limb due to cancer or for 
leg amputations. Further research is needed in these 
areas. This procedure is not being considered for Journal of Medicine and Life Volume 4, Issue 3, July‐September 2011 
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individuals whose injury is limited to fingers. The 
prospective patient should otherwise be healthy. 
Tests required for further evaluation include the 
following, but are not limited to: 
  X-rays 
  Extensive blood work 
  Physical measurements of the affected limb 
  Psychiatric evaluation and psychological 
projective testing 
  Consults with transplant surgeon, hand and 
microsurgeon, social worker, physical therapist, orthotist, 
primary care physician and other physician disciplines as 
appropriate 
  Other tests as indicated such as gastrointestinal 
tests, etc. 
Donated limbs would come from brain dead 
living donors similar to solid organ transplants. From a 
surgical point of view, harvesting tissues from a cadaveric 
donor gives several advantages which free the surgeon 
from the major constraints of traditional reconstruction. 
First, tissue allotransplantation obtains the preeminent 
objective of any tissue reconstruction; the " like with like " 
replacement, … where a thumb would be reconstructed 
with a thumb but not with a toe and another major 
advantage of allografts is the avoidance of any donor site 
morbidity which liberates the surgeon from the dilemma of 
healthy tissue destruction, a drawback of any 
reconstruction by autologus tissues [3]. 
Composite tissue allotransplantation is not a new 
technique, but a new practice, that couples the rules of 
microsurgical reconstruction and the rules of human 
organ transplantation. The world experience in human 
hand transplantation to date includes 50 transplants 
performed in 36 recipients (www.handregistry.com). 
Overall the functional outcomes and patient satisfaction 
have been reported to be good [5,6]. Recovery of motor 
function enabled the patients to perform most daily 
activities, including eating, driving, grasping objects, riding 
a bicycle or a motorbike, shaving, using the telephone 
and writing [7].  
A hand transplant, unlike a solid organ 
transplant, involves multiple tissues (skin, muscle, tendon, 
bone, cartilage, fat, nerves and blood vessels) and can be 
considered the “gold standard” in CTA. Accordingly, no 
other organ or tissue transplant matches the hand 
transplant in its immunogenicity as well as complexity [4]. 
In that experience, the number of acute rejection episodes 
during the first year has been high when compared to 
more recent reports in organ transplantation. Reports 
indicate that the majority of patients demonstrated at least 
one episode of acute rejection in the first year, and that 
skin was the primary target of the immune response [8-
13]. Repeated episodes were observed in some patients 
beyond the first year after transplantation [11-12]. The 
high frequency and severity of acute rejection in hand 
transplantation has been attributed to the high 
immunogenicity of the skin, which forms a major 
component of the graft. The high antigenicity of the skin 
can, in part, be related to the high proportion of potent 
antigen-presenting cells (Langerhans cells) and 
keratinocytes that express major histocompatibility 
complex (MHC) I constitutively, and MHC II, intercellular 
adhesion molecule 1 (ICAM)-I and proinflammatory 
cytokines upon stimulation [14,15]. Also, viral infections, 
in particular cytomegalovirus (CMV), have been 
postulated to trigger the episodes [16]. A major focus of 
current transplantation research is the development of 
strategies to obviate the need for immunosuppressive 
drugs by inducing specific tolerance to transplanted 
tissues. Strict definitions of transplantation tolerance 
include impaired responses to donor antigens with 
maintenance of immune responsiveness to third-party and 
non-donor antigens. Development of assays that allow us 
to monitor the current state of an immune response 
(rejection/tolerance) is of great interest and  requires an 
in-depth understanding of the complex and rare 
phenomenon of tolerance. The rarity of spontaneous 
transplantation tolerance and the difficulty of identifying 
such individuals pose major challenges in studying 
tolerance. In addition, the mechanisms of tolerance 
probably are numerous, may change over time, and vary 
depending on the organs involved. It now has become 
increasingly clear that tolerance in experimental rodent 
transplant models may differ from clinical transplantation 
in humans. 
 
How Can We Measure Immunologic Tolerance 
in Humans? Immune monitoring assays that currently are 
in development can be divided broadly into two major 




The development of immunologic memory and 
antigen specificity are hallmarks of the adaptive immune 
system. Therefore, assays that evaluate donor-specific 
responses of recipient lymphocytes are likely to be 
informative in transplantation. Traditional assays of  T cell 
reactivity that reflect antigen-specific responses include 
the  mixed leukocyte reaction (MLR), the cytotoxic T 
lymphocyte  (CTL) assay, the ELISA, and the limiting 
dilution assay. With the exception of the CTL assay, the 
results of these assays have not been shown consistently 
to be correlated with the development of tolerance or the 
ability to wean immunosuppression. The promising new T 
cell assays are: 
ELISPOT Assay:  is a hybrid that combines 
features of a MLR  and an ELISA assay in that 
responder/recipient T cells are cultured with inactivated 
stimulator/donor or third-party cells in tissue culture plates 
that are coated with an antibody that is specific for the 
cytokine of interest (many cytokines have been studied, 
including IFN-γ, IL-2, IL-4, IL-5, and IL-10). After a fairly 
brief culture period, the cells are washed away and the Journal of Medicine and Life Volume 4, Issue 3, July‐September 2011 
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bound cytokine is detected, using labeled secondary 
antibodies and an automated plate reader. Each spot that 
is detected represents a cell that had been primed to the 
stimulating antigen(s) in vivo (effector or memory T cells). 
Thus, this assay measures the frequency of previously 
activated or memory T cells that respond to donor 
antigens by producing a selected cytokine rather than the 
total amount of cytokine that is produced and secreted 
into supernatant. Obtaining and storing sufficient numbers 
of donor cells to perform the assay repeatedly is a 
practical limitation, particularly in recipients of deceased-
donor organs. 
Transvivo delayed-type hypersensitivity (DTH) 
assay: cells that are isolated from patients after 
transplantation are injected into the footpads or ears of 
immunodeficient mice together with donor antigen (Figure 
3). Recipient cells that respond to donor antigen produce 
a DTH reaction that is quantified by measuring the 
resultant swelling with a caliper. Like the ELISPOT assay, 
recipient T cells can be exposed to donor antigen in the 
form of whole, inactivated cells or donor proteins. A study 
of three functionally tolerant transplant recipients 
demonstrated that all three had intact DTH responses to 
third-party stimulator cells but absent DTH responses to 
donor antigens [18]. The transvivo DTH assay may be 
more useful for detecting patients with established 
tolerance than for making predictions about which 
patients who still are receiving immunosuppressive drugs 
may develop tolerance in the future. 
Tetramer Staining: Tetramers consist of four 
MHC-peptide complexes that are linked covalently to a 
fluorochrome (Figure 4). Such multimeric  peptide-MHC 
complexes can bind to the TCR of T cells that are specific 
for the peptide-MHC molecule complex [19]. The major 
potential of MHC tetramers is the direct visualization of 
antigen- specific T cells in vivo regardless of their function 
or ability  to produce cytokines  and the possibility of 
monitoring peptide-specific T cells over time with very 
small volumes of blood. MHC tetramers were used 
recently to monitor minor-histocompatibility antigen-
specific T cells in bone marrow recipients [20] and may 
have the potential for monitoring multiple autoimmune 
diseases [19]. 
Measurement of Cell Proliferation by carboxy-
fluorescein diacetate succinimidyl ester (CFSE) Labeling: 
This assay measures the proliferative response of 
recipient lymphocytes that are cultured or stimulated with 
inactivated donor cells for a period of several days. Flow 
cytometry has been used to measure the dilution of the 
dye CFSE that segregates equally between daughter cells 
with each cell doubling. Despite the theoretic appeal of 
this assay, to date, no human studies have demonstrated 
a correlation between donor antigen–induced proliferation 
and the ability to wean immunosuppression or the 
development of tolerance. 
Flow Cytometric Detection of Intracellular 
Cytokines:  This method allows the individual 
characterization of a large number of cells. With 
multiparametric staining, it can demonstrate coexpression 
of different cytokines in individual cells. However, this 
assay involves specific activation procedures and use of 
inhibitors of intracellular transport, which can limit the 
viability of the cells. Another issue is the limited sensitivity 
of the assay. 
 
Non–Antigen-Specific Assays 
Phenotyping of Recipient Immune Cells: 
Regulatory cells have been shown to be important for 
controlling immune responses in a number of pathogenic 
disease processes  as well as after transplantation. 
Several types of regulatory cells have been identified on 
the basis of their phenotypes, including  CD4+CD25high, 
CD3+CD4-CD8-, CD8+CD28-, and NK1.1+.  Although 
quantification and characterization of regulatory T  cells 
has the potential to identify patients with predilection 
toward “tolerance”  no systematic studies have been 
performed to date. 
Characterization of the TCR Repertoire: It has 
been hypothesized that the T cell component of the 
immune response to numerous self and foreign antigens 
is dominated by T cells using a limited number of TCR. 
This suggests a perturbation in the T cell repertoire that 
potentially  could be measured. TcLandscape is one 
method for characterizing changes in the TCR repertoire 
[21]. Briefly, this assay uses  quantitative PCR, gel 
electrophoresis and DNA sequencing to  determine the 
proportion of T cells that use each of the Vβ chains and to 
determine the CDR3 length distributions of each Vβ gene 
product. Depending on the  patient’s clinical status, 
overrepresented TCR could indicate the  expansion of 
alloreactive T cells that are capable of mediating allograft 
rejection or the expansion of protective regulatory T cells. 
One major issue with this method is lack of donor 
specificity. This may affect the interpretation of the results 
as  other antigens such as viral infections are likely to 
influence the T cell repertoire. 
T Cell Responses to Polyclonal, Non–Antigen-
Specific Stimulation: This assay is performed by 
stimulating whole blood (i.e., lymphocytes in the presence 
of circulating levels of immunosuppressive drugs) with 
phytohemagglutinin for 12 to 15 h. CD4_ T cells are 
isolated by magnetic bead selection. The extent of early 
CD4+ T cell activation is reflected by the synthesis and 
accumulation of intracellular ATP that is measured after 
cell lysis. This assay was designed to reflect the global or 
net state of immunosuppression and thereby facilitate 
decisions related to dosing immunosuppressive drugs 
after transplantation. 
Assays to Quantify Gene Expression: The basic 
concept of DNA microarrays is as follows: mRNA is 
reversetranscribed into cDNA, labeled with a fluorescent 
dye, and hybridized to the array. After any unbound 
sample is washed away, the array is scanned. The 
fluorescence intensity at a specific spot represents an Journal of Medicine and Life Volume 4, Issue 3, July‐September 2011 
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individual gene that correlates directly with the abundance 
of this gene in the sample. Unfortunately, genetic data 
sets that are obtained by this method usually are highly 
complex and require novel methods and software tools to 
handle the large volume of data generated. 
Proteomics: Several proteins can be generated 
from a single gene, depending  on how the genetic 
information is read (transcribed)  and how the resultant 
protein is modified after translation  (posttranslational 
modification) [22]. Analysis of mRNA expression  alone 
therefore is insufficient to determine whether the proteins 
encoded are really synthesized. Thus, the proteomic 
approach can complement nicely the gene expression 
findings. Protein microarrays are capable of providing a 
highthroughput approach to quantify both the amount of 
protein present and the function of individual proteins. 
In conclusion, continued success in clinical CTA 
over the next few years could convince the transplant 
community to shed its skepticism, that all attempts at CTA 
are ambitious and misguided. The CTA area is among the 
newest of transplant areas. The immunology of CTA 
grafts is complex, making CTA tolerance more difficult to 
achieve than organ tolerance. It needs to be emphasized 
that any episodes of acute rejection should be prevented 
for perfect restoration of function as well as to minimize 
the risk of chronic rejection in CTA. Efficacious, safe and 
ethical clinical tolerance protocols could improve patient 
acceptance of CTA by providing an alternative to chronic 
immunosuppression. The safe and successful clinical 
application of tolerance-inducing strategies in patients 
after transplantation will depend on identifying assays that 
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